
Dolby Laboratories (NYSE:DLB – Free Report) – Research analysts at Zacks Research raised their FY2026 earnings estimates for Dolby Laboratories in a report released on Thursday, August 20th. Zacks Research analyst Team now anticipates that the electronics maker will post earnings of $3.17 per share for the year, up from their previous forecast of $3.16. The consensus estimate for Dolby Laboratories’ current full-year earnings is $3.26 per share.
Dolby Laboratories (NYSE:DLB – Get Free Report) last announced its earnings results on Thursday, July 30th. The electronics maker reported $0.69 earnings per share for the quarter, beating analysts’ consensus estimates of $0.67 by $0.02. Dolby Laboratories had a net margin of 16.70% and a return on equity of 11.08%. The business had revenue of $305.00 million during the quarter, compared to the consensus estimate of $311.96 million. During the same quarter last year, the firm earned $0.78 earnings per share. The business’s revenue for the quarter was down 3.3% on a year-over-year basis. Dolby Laboratories has set its FY 2026 guidance at 4.250-4.400 EPS and its Q4 2026 guidance at 1.130-1.280 EPS.
Get Our Latest Analysis on Dolby Laboratories
Dolby Laboratories Stock Up 0.3%
Shares of DLB opened at $66.27 on Wednesday. The stock has a market cap of $6.21 billion, a P/E ratio of 28.20 and a beta of 0.80. The business’s 50 day moving average price is $55.01 and its 200-day moving average price is $58.51. Dolby Laboratories has a 52 week low of $48.26 and a 52 week high of $74.62.
Dolby Laboratories Dividend Announcement
The company also recently declared a quarterly dividend, which was paid on Wednesday, August 19th. Stockholders of record on Tuesday, August 11th were issued a dividend of $0.36 per share. The ex-dividend date was Tuesday, August 11th. This represents a $1.44 dividend on an annualized basis and a dividend yield of 2.2%. Dolby Laboratories’s dividend payout ratio is presently 61.28%.
Dolby Laboratories announced that its board has initiated a share buyback plan on Thursday, July 30th that permits the company to buyback $350.00 million in shares. This buyback authorization permits the electronics maker to repurchase up to 7% of its stock through open market purchases. Stock buyback plans are often an indication that the company’s leadership believes its stock is undervalued.
Insider Activity
In related news, SVP Shriram Revankar sold 3,000 shares of the business’s stock in a transaction that occurred on Friday, August 14th. The shares were sold at an average price of $62.71, for a total value of $188,130.00. Following the completion of the transaction, the senior vice president directly owned 73,274 shares in the company, valued at $4,595,012.54. The trade was a 3.93% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP John D. Couling sold 7,667 shares of the company’s stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $60.00, for a total value of $460,020.00. Following the completion of the transaction, the senior vice president directly owned 118,727 shares in the company, valued at $7,123,620. This trade represents a 6.07% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 27,705 shares of company stock worth $1,587,692 over the last 90 days. 37.93% of the stock is currently owned by insiders.
Institutional Trading of Dolby Laboratories
A number of institutional investors and hedge funds have recently modified their holdings of the business. Paragon Capital Management Inc. purchased a new position in shares of Dolby Laboratories in the 1st quarter worth $1,306,000. Hsbc Holdings PLC increased its position in Dolby Laboratories by 396.1% during the first quarter. Hsbc Holdings PLC now owns 31,259 shares of the electronics maker’s stock valued at $1,875,000 after acquiring an additional 24,958 shares during the last quarter. Norges Bank purchased a new stake in Dolby Laboratories during the fourth quarter valued at $54,966,000. Entropy Technologies LP bought a new position in Dolby Laboratories in the first quarter valued at about $1,674,000. Finally, Pacer Advisors Inc. boosted its position in Dolby Laboratories by 8.0% in the first quarter. Pacer Advisors Inc. now owns 516,292 shares of the electronics maker’s stock worth $31,008,000 after purchasing an additional 38,389 shares during the last quarter. Institutional investors own 58.56% of the company’s stock.
About Dolby Laboratories
Dolby Laboratories, Inc is a global leader in audio and imaging technologies, specializing in the development, licensing and deployment of solutions that enhance entertainment and communications experiences. The company’s core business revolves around creating advanced audio codecs, noise reduction systems and spatial sound technologies for a wide range of applications, including cinema, broadcast, gaming, streaming and personal devices. Dolby’s licensing model enables consumer electronics manufacturers, content creators and service providers to integrate its technologies into products such as televisions, smartphones, home theater systems and set-top boxes.
Among its flagship innovations are Dolby Atmos, an immersive audio format that delivers three-dimensional soundscapes for theaters and home systems; Dolby Digital and Dolby Digital Plus, widely adopted audio compression formats for broadcast and streaming; and Dolby Vision, a high-dynamic-range imaging technology that expands color, contrast and brightness in displays.
Further Reading
- Five stocks we like better than Dolby Laboratories
- Marzetti Stock Confirms Reversal on Earnings Strength, Dividend Growth
- Pathward’s Credit Scare Tests Its Comeback Story
- Wiring the AI Boom: Rumble’s $13.7B Pivot
- StoneX: Too Far Too Fast?
Receive News & Ratings for Dolby Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dolby Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
